SFE Investment Counsel cut its holdings in Pfizer Inc. (NYSE:PFE) by 10.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,531 shares of the biopharmaceutical company’s stock after selling 4,400 shares during the quarter. SFE Investment Counsel’s holdings in Pfizer were worth $1,403,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Grisanti Capital Management LLC lifted its stake in shares of Pfizer by 4.1% in the third quarter. Grisanti Capital Management LLC now owns 105,325 shares of the biopharmaceutical company’s stock worth $3,760,000 after buying an additional 4,170 shares during the last quarter. Northeast Investment Management lifted its stake in shares of Pfizer by 1.3% in the third quarter. Northeast Investment Management now owns 151,665 shares of the biopharmaceutical company’s stock worth $5,414,000 after buying an additional 2,008 shares during the last quarter. Synovus Financial Corp lifted its stake in shares of Pfizer by 6.3% in the third quarter. Synovus Financial Corp now owns 675,359 shares of the biopharmaceutical company’s stock worth $24,117,000 after buying an additional 40,245 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Pfizer by 1.0% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 6,464,938 shares of the biopharmaceutical company’s stock worth $231,769,000 after buying an additional 61,300 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its stake in shares of Pfizer by 2.7% in the third quarter. Citizens Financial Group Inc. RI now owns 123,246 shares of the biopharmaceutical company’s stock worth $4,400,000 after buying an additional 3,231 shares during the last quarter. Hedge funds and other institutional investors own 69.43% of the company’s stock.
In other Pfizer news, EVP Laurie J. Olson sold 19,000 shares of the stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $36.45, for a total transaction of $692,550.00. Following the sale, the executive vice president now owns 98,644 shares of the company’s stock, valued at approximately $3,595,573.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director W Don Cornwell sold 5,223 shares of the stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $36.40, for a total transaction of $190,117.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 156,535 shares of company stock worth $5,647,222. 0.06% of the stock is owned by insiders.
Shares of Pfizer opened at $36.30 on Friday, MarketBeat Ratings reports. The firm has a market capitalization of $217.04 billion, a price-to-earnings ratio of 13.70, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer Inc. has a 52-week low of $32.32 and a 52-week high of $39.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.03. The firm had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.69 EPS. analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 1st. Stockholders of record on Friday, May 11th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. The ex-dividend date was Thursday, May 10th. Pfizer’s payout ratio is 51.32%.
PFE has been the subject of a number of analyst reports. Jefferies Financial Group set a $39.00 price objective on shares of Pfizer and gave the stock a “hold” rating in a research note on Monday, February 26th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Barclays cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $41.00 to $38.00 in a research note on Thursday, April 5th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, April 6th. Finally, Berenberg Bank reiterated a “neutral” rating and set a $37.00 target price on shares of Pfizer in a research note on Wednesday, April 11th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have given a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and a consensus price target of $40.27.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.